Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01188187 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT01188187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01188187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Lead sponsor
Achieve Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
June 30, 2014
Enrollment
1,022 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer